^
    1year
    Immune Profiling of Psoriasiform Toxicity to Immune Checkpoint Inhibitor Therapy (ASDP 2024)
    These data suggest that differential upregulation of cytokine signaling pathways may be responsible for immunotherapy-related psoriasiform reactions versus de novo psoriasis. Additional studies are required to elucidate the mechanism of these cutaneous irAEs further.
    Checkpoint inhibition • IO biomarker
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • FOXA1 (Forkhead Box A1) • IL17A (Interleukin 17A) • KRT19 (Keratin 19) • IL1B (Interleukin 1, beta)
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    over1year
    Crown-like structures are associated with changes in immune cell infiltrates and gene signatures in patients with primary invasive breast cancer (ESMO-BC 2024)
    RNA sequencing showed that genes involved in cell proliferation were upregulated, whereas genes involved in the regulation of anticancer immunity were downregulated in CLS patients. Conclusions CLS were associated with an inflammatory border and aggressive molecular and immunosuppressive phenotypes in the core of the tumour.
    Clinical • Gene Signature • IO biomarker • Immune cell
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • FCGR2A (Fc fragment of IgG receptor IIa) • FOXP3 (Forkhead Box P3) • FCGR2B (Fc Fragment Of IgG Receptor IIb)
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    almost2years
    Differences in Immune Gene Expression Signatures and Biological Pathways Between Intracholecystic Papillary-Tubular Neoplasm with Associated Invasive Gallbladder Adenocarcinoma and Conventional Gallbladder Adenocarcinoma (USCAP 2024)
    Our findings illustrate transcriptomic differences between GBC and ICPN_GBC. Noteworthy, ICPN_GBC displayed an enhanced anti-tumor immunity with predominant T helper 1 response, while GBC had a pro-tumor immune response with high regulatory T cells. The understanding of the immune biology and biological pathways of these tumors can potentially optimize precision oncology for gallbladder cancer patients.
    IO biomarker
    |
    CDH1 (Cadherin 1) • LGALS1 (Galectin 1) • EPCAM (Epithelial cell adhesion molecule) • CD99 (CD99 Molecule) • ITGA5 (Integrin Subunit Alpha 5) • NECTIN2 (Nectin Cell Adhesion Molecule 2) • OCLN (Occludin)
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    almost2years
    A transcriptomic approach to explore the immune landscape of patient with pancreatic ductal adenocarcinoma with prognostic impact. (ASCO-GI 2024)
    In this study, a prognostic transcriptomic-based signature of 14 genes has been defined and validated for PDAC. This signature clearly identifies two prognostic groups that could constitute the basis for tailored immunotherapy with specific IC inhibitors. LAG-3 is a promising target for immunotherapy in PDAC patients.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD4 (CD4 Molecule) • TBX21 (T-Box Transcription Factor 21) • BTLA (B And T Lymphocyte Associated) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5)
    |
    PD-1 overexpression • PD-1 expression • LAG3 overexpression
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    2years
    Genomic staging of multifocal lung squamous cell carcinomas is independent of the comprehensive morphologic assessment. (PubMed, J Thorac Oncol)
    Staging of multifocal LSCC based on morphologic assessment is unreliable. Comprehensive genomic analyses should be adopted for the staging of multifocal LSCC.
    Journal • IO biomarker
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    over2years
    GENE EXPRESSION PROFILING OF T(14;18)-NEGATIVE CD23+ FOLLICLE CENTER LYMPHOMA DEMONSTRATES ACTIVATION OF THE IL4/JAK/STAT6 PATHWAY AND A ROLE IN ITS PATHOGENESIS (ICML 2023)
    GEP identified two distinct groups within t(14;18)-neg FL, indicating different stages of differentiation of the neoplastic B cells. FLnegmut shows activation of STAT6 pathway through upregulation of CD23 and IL4R and by enrichment in GSEA and correlates with CD23 expression. Constitutive activation of STAT6 and consequent upregulation of CD23 prevent ongoing B cell differentiation in FLnegmut, precluding the cells from exiting the GC and adopting the state of activated B cell.
    IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • TNFRSF17 (TNF Receptor Superfamily Member 17) • JAK1 (Janus Kinase 1) • CD22 (CD22 Molecule) • PAX5 (Paired Box 5) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • S100A8 (S100 Calcium Binding Protein A8) • IRF4 (Interferon regulatory factor 4) • PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1) • SOCS1 (Suppressor Of Cytokine Signaling 1) • TYK2 (Tyrosine Kinase 2) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • CD40 (CD40 Molecule) • FCGR1A (Fc Fragment Of IgG Receptor Ia) • HLA-DMB (Major Histocompatibility Complex, Class II, DM Beta) • IL4 (Interleukin 4) • FCER2 (Fc Fragment Of IgE Receptor II) • FCRLA (Fc Receptor Like A) • IL4R (Interleukin 4 Receptor) • SLAMF7 (SLAM Family Member 7) • SOCS3 (Suppressor Of Cytokine Signaling 3) • TNFRSF13B (TNF Receptor Superfamily Member 13B)
    |
    SOCS1 mutation
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    over2years
    Tumor Microenvironment and Its Clinicopathologic and Prognostic Association in Cutaneous and Noncutaneous Angiosarcomas. (PubMed, Am J Clin Pathol)
    Our HTG analyses confirmed a high degree of tumor and microenvironment heterogeneity. Cutaneous ASs, ASs without MYC amplification, and ASs located in the head and neck area seem to be the most immunogenic subtypes in our series.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression • PD-L1 overexpression • MYC amplification • CD8 expression • PD-L1 amplification
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    almost3years
    Gene Expression Profile as a Therapeutic Biomarker for Classic Hodgkin Lymphoma Treated with Immunotherapy-Based Regimens (USCAP 2023)
    Background : PD-1 blockade treatment with nivolumab is effective in relapsed/refractory Classic Hodgkin Lymphoma (CHL)... IL13 and IL15 modulation may be a logical objective for future therapeutic strategies since their role in proliferation of HL-derived cell-lines in addition to JAK-STAT and MAPK signaling activation. Likewise, SOCS3 for its suppressive role in JAK-STAT pathway. Other dysregulated genes in our series with potential therapeutic targets should be SMAD7, FADD, NFKB1, and MAPK11due to their involvement in variety of process including cell growth and differentiation, apoptosis as well as immune response .
    PD(L)-1 Biomarker • Gene Expression Profile • IO biomarker
    |
    MAP2K1 (Mitogen-activated protein kinase kinase 1) • CCND1 (Cyclin D1) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • IL2 (Interleukin 2) • IL7R (Interleukin 7 Receptor) • S100A8 (S100 Calcium Binding Protein A8) • FADD (Fas associated via death domain) • MAPK1 (Mitogen-activated protein kinase 1) • ROR2 (Receptor Tyrosine Kinase Like Orphan Receptor 2) • S100A9 (S100 Calcium Binding Protein A9) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • CCL2 (Chemokine (C-C motif) ligand 2) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • TNFRSF4 (TNF Receptor Superfamily Member 4) • IL1A (Interleukin 1, alpha) • IL32 (Interleukin 32) • MLANA (Melan-A) • BAG4 (BAG Cochaperone 4) • CCL22 (C-C Motif Chemokine Ligand 22) • CDC20 (Cell Division Cycle 20) • CTSL (Cathepsin L) • ERCC6 (Excision repair cross-complementation group 6) • IL13 (Interleukin 13) • IL15 (Interleukin 15) • IL22 (Interleukin 22) • SMAD7 (SMAD Family Member 7) • ST6GAL1 (ST6 Beta-Galactoside Alpha-2,6-Sialyltransferase 1) • CD80 (CD80 Molecule) • CDCA8 (Cell Division Cycle Associated 8) • CDK3 (Cyclin Dependent Kinase 3) • CENPA (Centromere protein A) • HNF1A (HNF1 Homeobox A) • IFNL3 (Interferon Lambda 3) • IRAK1 (Interleukin 1 Receptor Associated Kinase 1) • KIF4A (Kinesin Family Member 4A) • KLRB1 (Killer Cell Lectin Like Receptor B1) • LGALS9 (Galectin 9) • MAGEA1 (MAGE Family Member A1) • MAGEC2 (MAGE Family Member C2) • MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4) • MAPK11 (Mitogen-Activated Protein Kinase 11) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA) • PATZ1 (POZ/BTB And AT Hook Containing Zinc Finger 1) • PDHA1 (Pyruvate Dehydrogenase E1 Subunit Alpha 1) • POU2AF1 (POU Class 2 Homeobox Associating Factor 1) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A) • SOCS3 (Suppressor Of Cytokine Signaling 3) • TGFBR1 (Transforming Growth Factor Beta Receptor 1) • TGIF2 (TGFB Induced Factor Homeobox 2)
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    |
    Opdivo (nivolumab)
    almost3years
    Prognostic classification of endometrial cancer according to transcriptomic-based immunophenotype (ESMO-GC 2023)
    These findings could be useful in the clinical management of the disease, constituting an open window in the selection of EC patients for immunotherapy. Legal entity responsible for the study The authors.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CDK4 (Cyclin-dependent kinase 4) • TGFB1 (Transforming Growth Factor Beta 1) • TRIP13 (Thyroid Hormone Receptor Interactor 13) • RFC4 (Replication Factor C Subunit 4)
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    3years
    LAG3+ tumor infiltrating lymphocytes predict outcome in treatment naïve triple negative breast carcinoma (SABCS 2022)
    1. LAG3 is a prognostic marker for TNBCs. 2.
    Tumor-infiltrating lymphocyte • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • LAG3 (Lymphocyte Activating 3)
    |
    LAG3 expression
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    over3years
    Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC. (PubMed, Clin Cancer Res)
    Our findings highlight immune gene programs that may underlie host tumor immunity and response to neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    over3years
    Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC (AACR 2022)
    Our findings highlight immune gene programs that may underlie host tumor immunity and response to neoadjuvant chemotherapy and chemoimmunotherapy in early-stage NSCLC.
    Clinical • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel